Logo image of MLEC

MOOLEC SCIENCE SA (MLEC) Stock Fundamental Analysis

NASDAQ:MLEC - Nasdaq - LU2559000059 - Common Stock - Currency: USD

8.25  -0.65 (-7.3%)

After market: 0.93 -7.32 (-88.73%)

Fundamental Rating

1

MLEC gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 90 industry peers in the Food Products industry. MLEC has a bad profitability rating. Also its financial health evaluation is rather negative. MLEC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MLEC has reported negative net income.
In the past year MLEC has reported a negative cash flow from operations.
In the past 5 years MLEC always reported negative net income.
In the past 5 years MLEC always reported negative operating cash flow.
MLEC Yearly Net Income VS EBIT VS OCF VS FCFMLEC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

MLEC has a worse Return On Assets (-237.33%) than 95.56% of its industry peers.
Looking at the Return On Equity, with a value of -600.34%, MLEC is doing worse than 91.11% of the companies in the same industry.
Industry RankSector Rank
ROA -237.33%
ROE -600.34%
ROIC N/A
ROA(3y)-73.27%
ROA(5y)N/A
ROE(3y)-207.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MLEC Yearly ROA, ROE, ROICMLEC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MLEC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MLEC Yearly Profit, Operating, Gross MarginsMLEC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -1K -2K -3K -4K -5K

More info and screens

1

2. Health

2.1 Basic Checks

MLEC does not have a ROIC to compare to the WACC, probably because it is not profitable.
MLEC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MLEC Yearly Shares OutstandingMLEC Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 10M 20M 30M
MLEC Yearly Total Debt VS Total AssetsMLEC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -3.75, we must say that MLEC is in the distress zone and has some risk of bankruptcy.
MLEC has a Altman-Z score of -3.75. This is amonst the worse of the industry: MLEC underperforms 84.44% of its industry peers.
MLEC has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of MLEC (0.03) is better than 80.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -3.75
ROIC/WACCN/A
WACC7.53%
MLEC Yearly LT Debt VS Equity VS FCFMLEC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

MLEC has a Current Ratio of 0.26. This is a bad value and indicates that MLEC is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of MLEC (0.26) is worse than 95.56% of its industry peers.
A Quick Ratio of 0.22 indicates that MLEC may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.22, MLEC is doing worse than 95.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.26
Quick Ratio 0.22
MLEC Yearly Current Assets VS Current LiabilitesMLEC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

3

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1100%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%948.41%

3.2 Future

MLEC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.84% yearly.
Based on estimates for the next years, MLEC will show a very strong growth in Revenue. The Revenue will grow by 106.59% on average per year.
EPS Next Y-32.6%
EPS Next 2Y-10.63%
EPS Next 3Y30.14%
EPS Next 5Y33.84%
Revenue Next Year15.44%
Revenue Next 2Y22.5%
Revenue Next 3Y137.77%
Revenue Next 5Y106.59%

3.3 Evolution

MLEC Yearly Revenue VS EstimatesMLEC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
MLEC Yearly EPS VS EstimatesMLEC Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MLEC. In the last year negative earnings were reported.
Also next year MLEC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MLEC Price Earnings VS Forward Price EarningsMLEC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MLEC Per share dataMLEC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

MLEC's earnings are expected to grow with 30.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.63%
EPS Next 3Y30.14%

More info and screens

0

5. Dividend

5.1 Amount

MLEC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOOLEC SCIENCE SA

NASDAQ:MLEC (5/27/2025, 6:02:59 PM)

After market: 0.93 -7.32 (-88.73%)

8.25

-0.65 (-7.3%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)04-16 2025-04-16/dmh
Earnings (Next)05-28 2025-05-28
Inst Owners0.18%
Inst Owner ChangeN/A
Ins Owners2.15%
Ins Owner ChangeN/A
Market Cap33.08M
Analysts82.86
Price TargetN/A
Short Float %1.89%
Short Ratio2.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.61%
Min EPS beat(2)1.96%
Max EPS beat(2)73.26%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-900%
EPS NY rev (3m)-900%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.51
P/FCF N/A
P/OCF N/A
P/B 3.72
P/tB 105.83
EV/EBITDA N/A
EPS(TTM)-1.21
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-2.34
FCFYN/A
OCF(TTM)-2.31
OCFYN/A
SpS0.66
BVpS2.22
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -237.33%
ROE -600.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.27%
ROA(5y)N/A
ROE(3y)-207.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.26
Quick Ratio 0.22
Altman-Z -3.75
F-Score4
WACC7.53%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1100%
EPS Next Y-32.6%
EPS Next 2Y-10.63%
EPS Next 3Y30.14%
EPS Next 5Y33.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%948.41%
Revenue Next Year15.44%
Revenue Next 2Y22.5%
Revenue Next 3Y137.77%
Revenue Next 5Y106.59%
EBIT growth 1Y-189.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year80.33%
EBIT Next 3Y25.49%
EBIT Next 5Y21.71%
FCF growth 1Y-506.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-498.72%
OCF growth 3YN/A
OCF growth 5YN/A